zanamivir - CISMeF

Preferred Label : zanamivir;

MeSH definition : A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.;

MeSH synonym : 5-acetylamino-2,6-anhydro-4-guanidino-3,4,5-trideoxy-d-galacto-non-enoic acid; 4-guanidino-2-deoxy-2,3-didehydro-n-acetylneuraminic acid; 2,3-didehydro-2,4-dideoxy-4-guanidino-n-acetyl-d-neuraminic acid; 4 guanidino neu5ac2en; 4-guanidino-2,4-dideoxy-2,3-didehydro-n-acetylneuraminic acid; 4 guanidino 2 deoxy 2,3 didehydro n acetylneuraminic acid; acid, 4-guanidino-2-deoxy-2,3-didehydro-n-acetylneuraminic; 2,3-didehydro-2,4-dideoxy-4-guanidinyl-n-acetylneuraminic acid; 4-guanidino-neu5ac2en;

CISMeF synonym : zanamivir GlaxoSmithKline brand; biota brand of zanamivir; zanamivir biota brand; glaxo wellcome brand of zanamivir; GlaxoSmithKline brand of zanamivir;

MeSH hyponym : relenza; GG 167; GG167; GG-167;

MeSH CAS label : 5-acetylamino-4-guanidino-6-(1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid;

MeSH Related Number : 139110-80-8 (Zanamivir);

Registry Number MeSH : 139110-80-8;

Wikipedia link : https://en.wikipedia.org/wiki/Zanamivir;

Is substance : O;

UNII : L6O3XI777I;

InChIKey : ARAIBEBZBOPLMB-UFGQHTETSA-N;

Details

Origin ID

D053243;

UMLS CUI

C0216660;

ATC code(s)
- zanamivir [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- zanamivir [Substance BNPC]
Currated CISMeF NLP mapping
- Zanamivir [LOINC component]
- Zanamivir [ICD-11 Extension code]
- Zanamivir [SMS substance]
- Zanamivir [NCIt concept]
- Zanamivir (substance) [SNOMED CT concept]
Pharmacological action(s)
- antiviral agents [MeSH Descriptor]
- enzyme inhibitors [MeSH Descriptor]
Record concept(s)
- GG 167 [MeSH concept]
- relenza [MeSH concept]
- zanamivir [MeSH concept]
Related MeSH Supplementary Concept(s)
- BTA938 [MeSH Supplementary Concept]
- CS 8958 [MeSH Supplementary Concept]
- laninamivir [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing zanamivir (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Product containing zanamivir (medicinal product) [SNOMED CT concept]
- Zanamivir [LOINC component]
- Zanamivir [NCIt concept]
- Zanamivir (substance) [SNOMED CT concept]
- zanamivir [ATC Code]
- zanamivir [Substance BNPC]
Validated automatic mappings to BTNT
- zanamivir [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients